Lexicon names new drug candidate for glaucoma

LX7101 is a small molecule compound that may have application in treating glaucoma by lowering fluid pressure in the eye through a new mechanism of action.

Lexicon said that its drug candidate, LX7101, reduces intraocular pressure by enhancing the outflow facility of the eye. Increased resistance to fluid outflow facility is thought to be a major contributing factor to the higher incidence of glaucoma that is observed as people age.

Arthur Sands, president and CEO, said: “Our drug discovery strategy is continuing to produce a pipeline of novel programs with significant potential to advance medicine. LX7101 is now the sixth drug discovery program to enter formal preclinical development as part of Lexicon’s 10TO10 program.”